Unintentional injection of a dexamethasone implant into the crystalline lens: a case report.
Andrés Lisker CervantesNicolás CrimSantiago García-ArroyoVirgilio Morales-CantónRaúl Velez MontoyaPublished in: Arquivos brasileiros de oftalmologia (2020)
The intravitreal dexamethasone implant is a sustained-release anti-inflammatory drug system that releases 0.7 mg of dexamethasone into the vitreous cavity. The following case report describes a rare complication: accidental injection of the dexamethasone implant into the crystalline lens. A 73-year-old woman was diagnosed with central retina vein occlusion and cystoid macular edema. Initial tSreatment included three monthly intravitreal doses of anti-vascular endothelial growth factor treatment, which was not successful. Treatment was then modified to an intravitreal dexamethasone implant. Ten weeks later, the implant was observed in the posterior cortex of the crystalline lens. Because no improvement had occurred, the patient underwent phacoemulsification surgery, during which part of the lens migrated into the vitreous cavity. Therefore, 23-gauge pars plana complete vitrectomy was performed with trans-surgical administration of intravitreal aflibercept. Crystalline lens injury due to an intravitreal dexamethasone implant is a rare complication and typically results from the injection procedure. Immediate surgical or conservative approaches should be considered on an individual basis.
Keyphrases
- vascular endothelial growth factor
- diabetic retinopathy
- age related macular degeneration
- high dose
- low dose
- soft tissue
- cataract surgery
- case report
- endothelial cells
- room temperature
- ultrasound guided
- optical coherence tomography
- minimally invasive
- anti inflammatory
- emergency department
- percutaneous coronary intervention
- coronary artery bypass
- combination therapy
- electronic health record